Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
NGL FINE CHM ADCOCK INGRAM |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
NGL FINE CHM Mar-23 |
ADCOCK INGRAM Jun-14 |
NGL FINE CHM/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 2,569 | 332 | - | |
Low | Rs | 1,161 | 240 | - | |
Sales per share (Unadj.) | Rs | 450.0 | 98.8 | - | |
Earnings per share (Unadj.) | Rs | 33.2 | -24.9 | - | |
Cash flow per share (Unadj.) | Rs | 51.4 | -20.6 | - | |
Dividends per share (Unadj.) | Rs | 1.75 | 0 | - | |
Avg Dividend yield | % | 0.1 | 0 | - | |
Book value per share (Unadj.) | Rs | 360.1 | 77.5 | - | |
Shares outstanding (eoy) | m | 6.18 | 168.78 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 4.1 | 2.9 | 143.2% | |
Avg P/E ratio | x | 56.2 | -11.5 | -489.6% | |
P/CF ratio (eoy) | x | 36.3 | -13.9 | -261.6% | |
Price / Book Value ratio | x | 5.2 | 3.7 | 140.5% | |
Dividend payout | % | 5.3 | 0 | - | |
Avg Mkt Cap | Rs m | 11,523 | 48,236 | 23.9% | |
No. of employees | `000 | NA | 4.3 | 0.0% | |
Total wages/salary | Rs m | 369 | 3,027 | 12.2% | |
Avg. sales/employee | Rs Th | 0 | 3,883.3 | - | |
Avg. wages/employee | Rs Th | 0 | 705.2 | - | |
Avg. net profit/employee | Rs Th | 0 | -978.5 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 2,781 | 16,671 | 16.7% | |
Other income | Rs m | 55 | 117 | 47.4% | |
Total revenues | Rs m | 2,836 | 16,788 | 16.9% | |
Gross profit | Rs m | 350 | -2,889 | -12.1% | |
Depreciation | Rs m | 113 | 720 | 15.7% | |
Interest | Rs m | 18 | 452 | 4.1% | |
Profit before tax | Rs m | 274 | -3,943 | -6.9% | |
Minority Interest | Rs m | 0 | -11 | -0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 69 | 246 | 27.9% | |
Profit after tax | Rs m | 205 | -4,201 | -4.9% | |
Gross profit margin | % | 12.6 | -17.3 | -72.5% | |
Effective tax rate | % | 25.1 | -6.2 | -401.6% | |
Net profit margin | % | 7.4 | -25.2 | -29.3% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 1,627 | 12,210 | 13.3% | |
Current liabilities | Rs m | 583 | 6,870 | 8.5% | |
Net working cap to sales | % | 37.5 | 32.0 | 117.2% | |
Current ratio | x | 2.8 | 1.8 | 157.0% | |
Inventory Days | Days | 65 | 111 | 58.8% | |
Debtors Days | Days | 865 | 124 | 697.6% | |
Net fixed assets | Rs m | 1,244 | 7,117 | 17.5% | |
Share capital | Rs m | 31 | 77 | 39.9% | |
Net worth | Rs m | 2,225 | 13,085 | 17.0% | |
Long term debt | Rs m | 21 | 4,598 | 0.5% | |
Total assets | Rs m | 2,871 | 24,719 | 11.6% | |
Interest coverage | x | 15.9 | -7.7 | -205.9% | |
Debt to equity ratio | x | 0 | 0.4 | 2.7% | |
Sales to assets ratio | x | 1.0 | 0.7 | 143.6% | |
Return on assets | % | 7.8 | -15.2 | -51.3% | |
Return on equity | % | 9.2 | -32.1 | -28.7% | |
Return on capital | % | 13.0 | -19.8 | -65.6% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 353 | 1,423 | 24.8% | |
From Investments | Rs m | -270 | -437 | 61.8% | |
From Financial Activity | Rs m | -11 | 4,173 | -0.3% | |
Net Cashflow | Rs m | 72 | 5,159 | 1.4% |
Compare NGL FINE CHM With: ACTAVIS (US) MYLAN (US) TEVA PHARMA (Israel)
Compare NGL FINE CHM With: SMS LIFESCIENCES INDIA VEERHEALTH CARE IND. SWIFT ISTREET NETWORK TTK HEALTHCARE
Asian shares edged higher on Wednesday as anxious investors dared to hope AI-diva Nvidia could meet sky-high expectations, while keeping a wary eye on the outlook for US and UK interest rates.